The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
The global Gefitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Gefitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Gefitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Gefitinib include AstraZeneca, Qilu Pharmaceutical, Natco Pharma, Celon Laboratories, Hetero Drugs, Dr Reddy's Laboratories, Zuventus Healthcare, United Biotech and Panacea Biotec, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Gefitinib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gefitinib.
Report Scope
The Gefitinib market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gefitinib market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gefitinib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Qilu Pharmaceutical
Natco Pharma
Celon Laboratories
Hetero Drugs
Dr Reddy's Laboratories
Zuventus Healthcare
United Biotech
Panacea Biotec
Cipla
Glenmark Pharmaceuticals
Nobel Ilac Sanayii Ve Ticaret
Accure Labs
Cadila Pharmaceuticals
Ethypharm
Flagship Biotech International
Globela Pharma
Jodas Expoim
Nishchay Pharmaceuticals
Sichuan Xieli Pharmaceutical
Segment by Type
10 Tables/Box
30 Tables/Box
90 Tables/Box
Segment by Application
Hospital
Clinic
Drug Center
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gefitinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Gefitinib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
The global Gefitinib market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Gefitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Gefitinib is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Gefitinib include AstraZeneca, Qilu Pharmaceutical, Natco Pharma, Celon Laboratories, Hetero Drugs, Dr Reddy's Laboratories, Zuventus Healthcare, United Biotech and Panacea Biotec, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Gefitinib, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gefitinib.
Report Scope
The Gefitinib market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Gefitinib market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Gefitinib manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Qilu Pharmaceutical
Natco Pharma
Celon Laboratories
Hetero Drugs
Dr Reddy's Laboratories
Zuventus Healthcare
United Biotech
Panacea Biotec
Cipla
Glenmark Pharmaceuticals
Nobel Ilac Sanayii Ve Ticaret
Accure Labs
Cadila Pharmaceuticals
Ethypharm
Flagship Biotech International
Globela Pharma
Jodas Expoim
Nishchay Pharmaceuticals
Sichuan Xieli Pharmaceutical
Segment by Type
10 Tables/Box
30 Tables/Box
90 Tables/Box
Segment by Application
Hospital
Clinic
Drug Center
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Gefitinib manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Gefitinib in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Gefitinib Market Overview
1.1 Product Overview and Scope of Gefitinib
1.2 Gefitinib Segment by Type
1.2.1 Global Gefitinib Market Value Comparison by Type (2024-2030)
1.2.2 10 Tables/Box
1.2.3 30 Tables/Box
1.2.4 90 Tables/Box
1.3 Gefitinib Segment by Application
1.3.1 Global Gefitinib Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Others
1.4 Global Gefitinib Market Size Estimates and Forecasts
1.4.1 Global Gefitinib Revenue 2019-2030
1.4.2 Global Gefitinib Sales 2019-2030
1.4.3 Global Gefitinib Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Gefitinib Market Competition by Manufacturers
2.1 Global Gefitinib Sales Market Share by Manufacturers (2019-2024)
2.2 Global Gefitinib Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Gefitinib Average Price by Manufacturers (2019-2024)
2.4 Global Gefitinib Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Gefitinib, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Gefitinib, Product Type & Application
2.7 Gefitinib Market Competitive Situation and Trends
2.7.1 Gefitinib Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Gefitinib Players Market Share by Revenue
2.7.3 Global Gefitinib Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Gefitinib Retrospective Market Scenario by Region
3.1 Global Gefitinib Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Gefitinib Global Gefitinib Sales by Region: 2019-2030
3.2.1 Global Gefitinib Sales by Region: 2019-2024
3.2.2 Global Gefitinib Sales by Region: 2025-2030
3.3 Global Gefitinib Global Gefitinib Revenue by Region: 2019-2030
3.3.1 Global Gefitinib Revenue by Region: 2019-2024
3.3.2 Global Gefitinib Revenue by Region: 2025-2030
3.4 North America Gefitinib Market Facts & Figures by Country
3.4.1 North America Gefitinib Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Gefitinib Sales by Country (2019-2030)
3.4.3 North America Gefitinib Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Gefitinib Market Facts & Figures by Country
3.5.1 Europe Gefitinib Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Gefitinib Sales by Country (2019-2030)
3.5.3 Europe Gefitinib Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Gefitinib Market Facts & Figures by Country
3.6.1 Asia Pacific Gefitinib Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Gefitinib Sales by Country (2019-2030)
3.6.3 Asia Pacific Gefitinib Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Gefitinib Market Facts & Figures by Country
3.7.1 Latin America Gefitinib Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Gefitinib Sales by Country (2019-2030)
3.7.3 Latin America Gefitinib Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Gefitinib Market Facts & Figures by Country
3.8.1 Middle East and Africa Gefitinib Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Gefitinib Sales by Country (2019-2030)
3.8.3 Middle East and Africa Gefitinib Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Gefitinib Sales by Type (2019-2030)
4.1.1 Global Gefitinib Sales by Type (2019-2024)
4.1.2 Global Gefitinib Sales by Type (2025-2030)
4.1.3 Global Gefitinib Sales Market Share by Type (2019-2030)
4.2 Global Gefitinib Revenue by Type (2019-2030)
4.2.1 Global Gefitinib Revenue by Type (2019-2024)
4.2.2 Global Gefitinib Revenue by Type (2025-2030)
4.2.3 Global Gefitinib Revenue Market Share by Type (2019-2030)
4.3 Global Gefitinib Price by Type (2019-2030)
5 Segment by Application
5.1 Global Gefitinib Sales by Application (2019-2030)
5.1.1 Global Gefitinib Sales by Application (2019-2024)
5.1.2 Global Gefitinib Sales by Application (2025-2030)
5.1.3 Global Gefitinib Sales Market Share by Application (2019-2030)
5.2 Global Gefitinib Revenue by Application (2019-2030)
5.2.1 Global Gefitinib Revenue by Application (2019-2024)
5.2.2 Global Gefitinib Revenue by Application (2025-2030)
5.2.3 Global Gefitinib Revenue Market Share by Application (2019-2030)
5.3 Global Gefitinib Price by Application (2019-2030)
6 Key Companies Profiled
6.1 AstraZeneca
6.1.1 AstraZeneca Corporation Information
6.1.2 AstraZeneca Description and Business Overview
6.1.3 AstraZeneca Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.1.4 AstraZeneca Gefitinib Product Portfolio
6.1.5 AstraZeneca Recent Developments/Updates
6.2 Qilu Pharmaceutical
6.2.1 Qilu Pharmaceutical Corporation Information
6.2.2 Qilu Pharmaceutical Description and Business Overview
6.2.3 Qilu Pharmaceutical Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Qilu Pharmaceutical Gefitinib Product Portfolio
6.2.5 Qilu Pharmaceutical Recent Developments/Updates
6.3 Natco Pharma
6.3.1 Natco Pharma Corporation Information
6.3.2 Natco Pharma Description and Business Overview
6.3.3 Natco Pharma Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Natco Pharma Gefitinib Product Portfolio
6.3.5 Natco Pharma Recent Developments/Updates
6.4 Celon Laboratories
6.4.1 Celon Laboratories Corporation Information
6.4.2 Celon Laboratories Description and Business Overview
6.4.3 Celon Laboratories Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Celon Laboratories Gefitinib Product Portfolio
6.4.5 Celon Laboratories Recent Developments/Updates
6.5 Hetero Drugs
6.5.1 Hetero Drugs Corporation Information
6.5.2 Hetero Drugs Description and Business Overview
6.5.3 Hetero Drugs Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Hetero Drugs Gefitinib Product Portfolio
6.5.5 Hetero Drugs Recent Developments/Updates
6.6 Dr Reddy's Laboratories
6.6.1 Dr Reddy's Laboratories Corporation Information
6.6.2 Dr Reddy's Laboratories Description and Business Overview
6.6.3 Dr Reddy's Laboratories Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Dr Reddy's Laboratories Gefitinib Product Portfolio
6.6.5 Dr Reddy's Laboratories Recent Developments/Updates
6.7 Zuventus Healthcare
6.6.1 Zuventus Healthcare Corporation Information
6.6.2 Zuventus Healthcare Description and Business Overview
6.6.3 Zuventus Healthcare Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Zuventus Healthcare Gefitinib Product Portfolio
6.7.5 Zuventus Healthcare Recent Developments/Updates
6.8 United Biotech
6.8.1 United Biotech Corporation Information
6.8.2 United Biotech Description and Business Overview
6.8.3 United Biotech Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.8.4 United Biotech Gefitinib Product Portfolio
6.8.5 United Biotech Recent Developments/Updates
6.9 Panacea Biotec
6.9.1 Panacea Biotec Corporation Information
6.9.2 Panacea Biotec Description and Business Overview
6.9.3 Panacea Biotec Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Panacea Biotec Gefitinib Product Portfolio
6.9.5 Panacea Biotec Recent Developments/Updates
6.10 Cipla
6.10.1 Cipla Corporation Information
6.10.2 Cipla Description and Business Overview
6.10.3 Cipla Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Cipla Gefitinib Product Portfolio
6.10.5 Cipla Recent Developments/Updates
6.11 Glenmark Pharmaceuticals
6.11.1 Glenmark Pharmaceuticals Corporation Information
6.11.2 Glenmark Pharmaceuticals Gefitinib Description and Business Overview
6.11.3 Glenmark Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Glenmark Pharmaceuticals Gefitinib Product Portfolio
6.11.5 Glenmark Pharmaceuticals Recent Developments/Updates
6.12 Nobel Ilac Sanayii Ve Ticaret
6.12.1 Nobel Ilac Sanayii Ve Ticaret Corporation Information
6.12.2 Nobel Ilac Sanayii Ve Ticaret Gefitinib Description and Business Overview
6.12.3 Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Nobel Ilac Sanayii Ve Ticaret Gefitinib Product Portfolio
6.12.5 Nobel Ilac Sanayii Ve Ticaret Recent Developments/Updates
6.13 Accure Labs
6.13.1 Accure Labs Corporation Information
6.13.2 Accure Labs Gefitinib Description and Business Overview
6.13.3 Accure Labs Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Accure Labs Gefitinib Product Portfolio
6.13.5 Accure Labs Recent Developments/Updates
6.14 Cadila Pharmaceuticals
6.14.1 Cadila Pharmaceuticals Corporation Information
6.14.2 Cadila Pharmaceuticals Gefitinib Description and Business Overview
6.14.3 Cadila Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Cadila Pharmaceuticals Gefitinib Product Portfolio
6.14.5 Cadila Pharmaceuticals Recent Developments/Updates
6.15 Ethypharm
6.15.1 Ethypharm Corporation Information
6.15.2 Ethypharm Gefitinib Description and Business Overview
6.15.3 Ethypharm Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Ethypharm Gefitinib Product Portfolio
6.15.5 Ethypharm Recent Developments/Updates
6.16 Flagship Biotech International
6.16.1 Flagship Biotech International Corporation Information
6.16.2 Flagship Biotech International Gefitinib Description and Business Overview
6.16.3 Flagship Biotech International Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Flagship Biotech International Gefitinib Product Portfolio
6.16.5 Flagship Biotech International Recent Developments/Updates
6.17 Globela Pharma
6.17.1 Globela Pharma Corporation Information
6.17.2 Globela Pharma Gefitinib Description and Business Overview
6.17.3 Globela Pharma Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Globela Pharma Gefitinib Product Portfolio
6.17.5 Globela Pharma Recent Developments/Updates
6.18 Jodas Expoim
6.18.1 Jodas Expoim Corporation Information
6.18.2 Jodas Expoim Gefitinib Description and Business Overview
6.18.3 Jodas Expoim Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Jodas Expoim Gefitinib Product Portfolio
6.18.5 Jodas Expoim Recent Developments/Updates
6.19 Nishchay Pharmaceuticals
6.19.1 Nishchay Pharmaceuticals Corporation Information
6.19.2 Nishchay Pharmaceuticals Gefitinib Description and Business Overview
6.19.3 Nishchay Pharmaceuticals Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Nishchay Pharmaceuticals Gefitinib Product Portfolio
6.19.5 Nishchay Pharmaceuticals Recent Developments/Updates
6.20 Sichuan Xieli Pharmaceutical
6.20.1 Sichuan Xieli Pharmaceutical Corporation Information
6.20.2 Sichuan Xieli Pharmaceutical Gefitinib Description and Business Overview
6.20.3 Sichuan Xieli Pharmaceutical Gefitinib Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Sichuan Xieli Pharmaceutical Gefitinib Product Portfolio
6.20.5 Sichuan Xieli Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Gefitinib Industry Chain Analysis
7.2 Gefitinib Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Gefitinib Production Mode & Process
7.4 Gefitinib Sales and Marketing
7.4.1 Gefitinib Sales Channels
7.4.2 Gefitinib Distributors
7.5 Gefitinib Customers
8 Gefitinib Market Dynamics
8.1 Gefitinib Industry Trends
8.2 Gefitinib Market Drivers
8.3 Gefitinib Market Challenges
8.4 Gefitinib Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Gefitinib Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Gefitinib Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Gefitinib Market Competitive Situation by Manufacturers in 2023
Table 4. Global Gefitinib Sales (K Pcs) of Key Manufacturers (2019-2024)
Table 5. Global Gefitinib Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Gefitinib Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Gefitinib Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Gefitinib Average Price (USD/Pcs) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Gefitinib, Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Gefitinib, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Gefitinib, Product Type & Application
Table 12. Global Key Manufacturers of Gefitinib, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Gefitinib by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gefitinib as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Gefitinib Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Gefitinib Sales by Region (2019-2024) & (K Pcs)
Table 18. Global Gefitinib Sales Market Share by Region (2019-2024)
Table 19. Global Gefitinib Sales by Region (2025-2030) & (K Pcs)
Table 20. Global Gefitinib Sales Market Share by Region (2025-2030)
Table 21. Global Gefitinib Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Gefitinib Revenue Market Share by Region (2019-2024)
Table 23. Global Gefitinib Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Gefitinib Revenue Market Share by Region (2025-2030)
Table 25. North America Gefitinib Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Gefitinib Sales by Country (2019-2024) & (K Pcs)
Table 27. North America Gefitinib Sales by Country (2025-2030) & (K Pcs)
Table 28. North America Gefitinib Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Gefitinib Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Gefitinib Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Gefitinib Sales by Country (2019-2024) & (K Pcs)
Table 32. Europe Gefitinib Sales by Country (2025-2030) & (K Pcs)
Table 33. Europe Gefitinib Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Gefitinib Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Gefitinib Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Gefitinib Sales by Region (2019-2024) & (K Pcs)
Table 37. Asia Pacific Gefitinib Sales by Region (2025-2030) & (K Pcs)
Table 38. Asia Pacific Gefitinib Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Gefitinib Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Gefitinib Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Gefitinib Sales by Country (2019-2024) & (K Pcs)
Table 42. Latin America Gefitinib Sales by Country (2025-2030) & (K Pcs)
Table 43. Latin America Gefitinib Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Gefitinib Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Gefitinib Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Gefitinib Sales by Country (2019-2024) & (K Pcs)
Table 47. Middle East & Africa Gefitinib Sales by Country (2025-2030) & (K Pcs)
Table 48. Middle East & Africa Gefitinib Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Gefitinib Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Gefitinib Sales (K Pcs) by Type (2019-2024)
Table 51. Global Gefitinib Sales (K Pcs) by Type (2025-2030)
Table 52. Global Gefitinib Sales Market Share by Type (2019-2024)
Table 53. Global Gefitinib Sales Market Share by Type (2025-2030)
Table 54. Global Gefitinib Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Gefitinib Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Gefitinib Revenue Market Share by Type (2019-2024)
Table 57. Global Gefitinib Revenue Market Share by Type (2025-2030)
Table 58. Global Gefitinib Price (USD/Pcs) by Type (2019-2024)
Table 59. Global Gefitinib Price (USD/Pcs) by Type (2025-2030)
Table 60. Global Gefitinib Sales (K Pcs) by Application (2019-2024)
Table 61. Global Gefitinib Sales (K Pcs) by Application (2025-2030)
Table 62. Global Gefitinib Sales Market Share by Application (2019-2024)
Table 63. Global Gefitinib Sales Market Share by Application (2025-2030)
Table 64. Global Gefitinib Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Gefitinib Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Gefitinib Revenue Market Share by Application (2019-2024)
Table 67. Global Gefitinib Revenue Market Share by Application (2025-2030)
Table 68. Global Gefitinib Price (USD/Pcs) by Application (2019-2024)
Table 69. Global Gefitinib Price (USD/Pcs) by Application (2025-2030)
Table 70. AstraZeneca Corporation Information
Table 71. AstraZeneca Description and Business Overview
Table 72. AstraZeneca Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 73. AstraZeneca Gefitinib Product
Table 74. AstraZeneca Recent Developments/Updates
Table 75. Qilu Pharmaceutical Corporation Information
Table 76. Qilu Pharmaceutical Description and Business Overview
Table 77. Qilu Pharmaceutical Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 78. Qilu Pharmaceutical Gefitinib Product
Table 79. Qilu Pharmaceutical Recent Developments/Updates
Table 80. Natco Pharma Corporation Information
Table 81. Natco Pharma Description and Business Overview
Table 82. Natco Pharma Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 83. Natco Pharma Gefitinib Product
Table 84. Natco Pharma Recent Developments/Updates
Table 85. Celon Laboratories Corporation Information
Table 86. Celon Laboratories Description and Business Overview
Table 87. Celon Laboratories Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 88. Celon Laboratories Gefitinib Product
Table 89. Celon Laboratories Recent Developments/Updates
Table 90. Hetero Drugs Corporation Information
Table 91. Hetero Drugs Description and Business Overview
Table 92. Hetero Drugs Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 93. Hetero Drugs Gefitinib Product
Table 94. Hetero Drugs Recent Developments/Updates
Table 95. Dr Reddy's Laboratories Corporation Information
Table 96. Dr Reddy's Laboratories Description and Business Overview
Table 97. Dr Reddy's Laboratories Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 98. Dr Reddy's Laboratories Gefitinib Product
Table 99. Dr Reddy's Laboratories Recent Developments/Updates
Table 100. Zuventus Healthcare Corporation Information
Table 101. Zuventus Healthcare Description and Business Overview
Table 102. Zuventus Healthcare Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 103. Zuventus Healthcare Gefitinib Product
Table 104. Zuventus Healthcare Recent Developments/Updates
Table 105. United Biotech Corporation Information
Table 106. United Biotech Description and Business Overview
Table 107. United Biotech Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 108. United Biotech Gefitinib Product
Table 109. United Biotech Recent Developments/Updates
Table 110. Panacea Biotec Corporation Information
Table 111. Panacea Biotec Description and Business Overview
Table 112. Panacea Biotec Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 113. Panacea Biotec Gefitinib Product
Table 114. Panacea Biotec Recent Developments/Updates
Table 115. Cipla Corporation Information
Table 116. Cipla Description and Business Overview
Table 117. Cipla Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 118. Cipla Gefitinib Product
Table 119. Cipla Recent Developments/Updates
Table 120. Glenmark Pharmaceuticals Corporation Information
Table 121. Glenmark Pharmaceuticals Description and Business Overview
Table 122. Glenmark Pharmaceuticals Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 123. Glenmark Pharmaceuticals Gefitinib Product
Table 124. Glenmark Pharmaceuticals Recent Developments/Updates
Table 125. Nobel Ilac Sanayii Ve Ticaret Corporation Information
Table 126. Nobel Ilac Sanayii Ve Ticaret Description and Business Overview
Table 127. Nobel Ilac Sanayii Ve Ticaret Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 128. Nobel Ilac Sanayii Ve Ticaret Gefitinib Product
Table 129. Nobel Ilac Sanayii Ve Ticaret Recent Developments/Updates
Table 130. Accure Labs Corporation Information
Table 131. Accure Labs Description and Business Overview
Table 132. Accure Labs Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 133. Accure Labs Gefitinib Product
Table 134. Accure Labs Recent Developments/Updates
Table 135. Cadila Pharmaceuticals Corporation Information
Table 136. Cadila Pharmaceuticals Description and Business Overview
Table 137. Cadila Pharmaceuticals Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 138. Cadila Pharmaceuticals Gefitinib Product
Table 139. Cadila Pharmaceuticals Recent Developments/Updates
Table 140. Ethypharm Corporation Information
Table 141. Ethypharm Description and Business Overview
Table 142. Ethypharm Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 143. Ethypharm Gefitinib Product
Table 144. Ethypharm Recent Developments/Updates
Table 145. Flagship Biotech International Corporation Information
Table 146. Flagship Biotech International Description and Business Overview
Table 147. Flagship Biotech International Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 148. Flagship Biotech International Gefitinib Product
Table 149. Flagship Biotech International Recent Developments/Updates
Table 150. Globela Pharma Corporation Information
Table 151. Globela Pharma Description and Business Overview
Table 152. Globela Pharma Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 153. Globela Pharma Gefitinib Product
Table 154. Globela Pharma Recent Developments/Updates
Table 155. Jodas Expoim Corporation Information
Table 156. Jodas Expoim Description and Business Overview
Table 157. Jodas Expoim Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 158. Jodas Expoim Gefitinib Product
Table 159. Jodas Expoim Recent Developments/Updates
Table 160. Nishchay Pharmaceuticals Corporation Information
Table 161. Nishchay Pharmaceuticals Description and Business Overview
Table 162. Nishchay Pharmaceuticals Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 163. Nishchay Pharmaceuticals Gefitinib Product
Table 164. Nishchay Pharmaceuticals Recent Developments/Updates
Table 165. Sichuan Xieli Pharmaceutical Corporation Information
Table 166. Sichuan Xieli Pharmaceutical Description and Business Overview
Table 167. Sichuan Xieli Pharmaceutical Gefitinib Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2019-2024)
Table 168. Sichuan Xieli Pharmaceutical Gefitinib Product
Table 169. Sichuan Xieli Pharmaceutical Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Gefitinib Distributors List
Table 173. Gefitinib Customers List
Table 174. Gefitinib Market Trends
Table 175. Gefitinib Market Drivers
Table 176. Gefitinib Market Challenges
Table 177. Gefitinib Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Gefitinib
Figure 2. Global Gefitinib Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Gefitinib Market Share by Type in 2023 & 2030
Figure 4. 10 Tables/Box Product Picture
Figure 5. 30 Tables/Box Product Picture
Figure 6. 90 Tables/Box Product Picture
Figure 7. Global Gefitinib Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Gefitinib Market Share by Application in 2023 & 2030
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Drug Center
Figure 12. Others
Figure 13. Global Gefitinib Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Gefitinib Market Size (2019-2030) & (US$ Million)
Figure 15. Global Gefitinib Sales (2019-2030) & (K Pcs)
Figure 16. Global Gefitinib Average Price (USD/Pcs) & (2019-2030)
Figure 17. Gefitinib Report Years Considered
Figure 18. Gefitinib Sales Share by Manufacturers in 2023
Figure 19. Global Gefitinib Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Gefitinib Players: Market Share by Revenue in 2023
Figure 21. Gefitinib Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Gefitinib Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Gefitinib Sales Market Share by Country (2019-2030)
Figure 24. North America Gefitinib Revenue Market Share by Country (2019-2030)
Figure 25. U.S. Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Gefitinib Sales Market Share by Country (2019-2030)
Figure 28. Europe Gefitinib Revenue Market Share by Country (2019-2030)
Figure 29. Germany Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Gefitinib Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Gefitinib Revenue Market Share by Region (2019-2030)
Figure 36. China Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. Taiwan Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Philippines Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 46. Latin America Gefitinib Sales Market Share by Country (2019-2030)
Figure 47. Latin America Gefitinib Revenue Market Share by Country (2019-2030)
Figure 48. Mexico Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Brazil Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Argentina Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 51. Middle East & Africa Gefitinib Sales Market Share by Country (2019-2030)
Figure 52. Middle East & Africa Gefitinib Revenue Market Share by Country (2019-2030)
Figure 53. Turkey Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. Saudi Arabia Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. U.A.E Gefitinib Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 56. Global Sales Market Share of Gefitinib by Type (2019-2030)
Figure 57. Global Revenue Market Share of Gefitinib by Type (2019-2030)
Figure 58. Global Gefitinib Price (USD/Pcs) by Type (2019-2030)
Figure 59. Global Sales Market Share of Gefitinib by Application (2019-2030)
Figure 60. Global Revenue Market Share of Gefitinib by Application (2019-2030)
Figure 61. Global Gefitinib Price (USD/Pcs) by Application (2019-2030)
Figure 62. Gefitinib Value Chain
Figure 63. Gefitinib Production Process
Figure 64. Channels of Distribution (Direct Vs Distribution)
Figure 65. Distributors Profiles
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
